Developer docs
API playgroundTry for free, no card

Search company profiles

Flagship Biosciences

Full company profile

uuid0005b16

Namestring
Flagship Biosciences
Legal namestring
Flagship Biosciences, Inc.
Websiteurl
flagshipbio.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Flagship Biosciences is a privately held, US-based contract research organization that delivers spatial biology, genomics, and histopathology services to pharmaceutical and biotechnology companies conducting drug development and clinical trials. Founded in 2009 and headquartered in Broomfield, Colorado, with a second laboratory in Morrisville, North Carolina acquired from Interpace Pharma Solutions in 2022, the company operates CLIA-certified, CAP-accredited, and New York State-permitted facilities. Its service catalog spans immunohistochemistry, multiplex immunofluorescence, in situ hybridization, digital spatial profiling, RNA sequencing, whole-exome and whole-genome sequencing, targeted NGS panels, gene expression analysis, qPCR/Sanger sequencing, flow cytometry, and anatomical pathology, sold through Statement-of-Work engagements on a custom-quote basis.

The company's technical backbone is its proprietary Flotilla image analysis platform, which applies machine learning algorithms to clinical tissue samples, performing tissue segmentation, cell identification, and spectral unmixing while collecting thousands of features per cell to build cellular databases. Expert board-certified pathologists and computational scientists guide this AI through quality control and artifact detection, and the company has published validated digital assays such as Tissue Insight 22C3 NSCLC in Scientific Reports. Flagship also integrates third-party sequencing and spatial profiling instruments — Illumina NovaSeq, NanoString nCounter and GeoMx, Leica whole-slide scanners — into its workflow, and partners with Genomenon, Paige, and Offspring Biosciences to extend its genomic interpretation, immuno-oncology software distribution, and transatlantic assay development footprint.

Flagship generates revenue through professional-services CRO engagements with enterprise pharma and biotech clients, with pricing driven by project scope, assay complexity, sample volume, regulatory requirements, and turnaround time on multi-year Statement-of-Work contracts. The company sells directly through enterprise field sales supported by a conference-heavy marketing program (AACR, ASCO, World CDx, Spatial Biology summits), scientific content, and a quarterly newsletter, and is recognized via the Frost & Sullivan 2023 North American Customer Value Leadership Award in AI-enabled digital pathology.

Short descriptiontext

Flagship Biosciences is a privately held CRO delivering AI-powered spatial biology, genomics, and histopathology services to pharmaceutical and biotech companies for clinical trials and companion diagnostic development. It operates CLIA-CAP-accredited laboratories in Colorado and North Carolina.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBroomfield, United States
HQ citystring
Broomfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial biology services, biomarker analytics, digital pathology, companion diagnostics, tissue imaging analysis
Industry5 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Contract Research Organization (Biomarker and Spatial Biology Services)
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Biomarker and Spatial Biology Laboratory Services
TypeProfessional Services
Description

Flagship Biosciences generates revenue through providing contract research organization (CRO) services including spatial biology, genomics, histopathology, and biomarker analytics to pharmaceutical and biotech companies for clinical trials. Revenue is project-based and service contract driven, typically scoped as Statement of Work agreements for specific assay development, testing, and analysis projects. The company operates CLIA-certified and CAP-accredited laboratories.

flagshipbio.com
2Regulatory and Companion Diagnostics Development Services
TypeProfessional Services
Description

Provides end-to-end regulatory strategy and companion diagnostic development services from early discovery through commercialization, including FDA interaction support, assay validation, and regulatory submission planning. Revenue generated through consulting and laboratory service engagements.

flagshipbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing for pharma and biotech clients
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by project scope, assay complexity, sample volume, regulatory requirements, and turnaround time. No public pricing tiers listed; all engagements are quote-based.

flagshipbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Flagship Biosciences provides AI-powered spatial biology, genomics, histopathology, and biomarker development services for pharmaceutical and biotech companies through CLIA-certified and CAP-accredited laboratories. Core offerings include immunohistochemistry (IHC), multiplex immunofluorescence (mIF), digital spatial profiling, in situ hybridization (RNAscope ISH), RNA sequencing, whole exome and whole genome sequencing, and regulatory support for companion diagnostic development, all powered by the proprietary Flotilla image analysis platform and supported by expert pathologist consultation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Proprietary digital assay Tissue Insight (TI) 22C3 NSCLC published in Scientific Reports for streamlining PD-L1 IHC quantification in NSCLC
Product overview1 text field

Flagship Biosciences is a technology-driven spatial biology and biomarker services company offering a comprehensive portfolio of laboratory and analytical services. The core offerings include Spatial Biology services (IHC, multiplex immunofluorescence, digital spatial profiling, and ISH), Genomics services (RNASeq, WES, WGS, targeted NGS panels, gene expression analysis, qPCR/Sanger sequencing), and Histopathology. These are supported by proprietary AI-powered image analysis technology (Flotilla platform), Computational Biology for data analysis, Biomarker Development, Regulatory Support for companion diagnostics, and Flow Cytometry. All services are delivered through a CLIA-certified, CAP-accredited laboratory with expert scientific consultation.

Product and service19 records
1Spatial Biology Services
CategorySpatial Biology
Description

Comprehensive spatial biology services combining multiplexed in situ RNA detection (RNAscope), multiplex immunofluorescence (mIF), digital spatial profiling (NanoString GeoMx), and IHC with AI-powered image analysis. Sold to pharmaceutical and biotech companies for biomarker discovery, assay development, and clinical trial support.

2Genomics Services
CategoryGenomics
Description

CLIA-certified, CAP-accredited DNA sequencing and gene expression services including RNASeq, Whole Exome Sequencing, Whole Genome Sequencing, targeted NGS panels, gene expression analysis (NanoString nCounter), and qPCR/Sanger sequencing. Supports biomarker discovery, oncology research, and precision medicine programs.

3Histopathology Services
CategoryHistopathology
Description

Histopathology services combining board-certified pathologist expertise with digital pathology and AI-powered analysis, including H&E, IHC, multiplex immunofluorescence, and special stains. Includes GLP and clinical trial support for pharma and biotech clients.

4Image Analysis Services
CategoryImage Analysis
Description

Cutting-edge imaging and proprietary image analysis software for tissue sample analysis at transcriptomics and proteomics levels, including multiplexed in situ RNA detection and multiplex immunohistochemical staining with AI and machine learning coupled with expert pathologist consultation.

5ISH (In Situ Hybridization) Services
CategorySpatial Biology
Description

RNA detection service using the RNAscope platform enabling highly sensitive, single-cell RNA detection within tissue samples for precise visualization of gene expression in native tissue context.

6mIF (multiplex immunofluorescence) Services
CategorySpatial Biology
Description

Advanced spatial biology service enabling simultaneous detection of multiple biomarkers on a single slide for immune profiling, biomarker co-localization, and pathway exploration. Combines custom panel development with proprietary image analysis and AI-driven quantification.

7Digital Spatial Profiling (DSP) Services
CategorySpatial Biology
Description

High-resolution biomarker expression analysis using the NanoString GeoMx platform, combining multiplexed RNA or protein quantification with precise spatial localization to uncover insights into tumor microenvironment, immune infiltration, and cellular heterogeneity.

8Biomarker Development Services
CategoryBiomarker Development
Description

Assay development, validation, and operationalization services for rare diseases, oncology, and other therapeutic areas. Includes a robust library of fit-for-purpose and validated singleplex, duplex, and multiplex panels using IHC, ISH, and multiplex IF modalities.

9Regulatory Support Services
CategoryCompanion Diagnostics
Description

End-to-end regulatory support for biomarker development from early discovery through commercialization, including gap analysis, assay development strategies, FDA interface, LDT development, cutoff determination, and regulatory submission planning for companion diagnostics.

10Computational Biology Services
CategoryData Science
Description

Data science services leveraging advanced analytical techniques for deriving insights from complex tissue image analysis and genomics data. Includes custom analysis using Bioconductor tools, StarAligner for RNA alignment, and DESeq2/GLMMer for differential expression models.

11RNASeq Service
CategoryGenomics
Description

RNA sequencing service for transcriptome analysis providing insights into gene expression, alternative splicing, and RNA editing across various sample types using the NovaSeq X Plus platform.

12Whole Genome Sequencing (WGS) Service
CategoryGenomics
Description

Comprehensive whole genome sequencing service using NovaSeq X Plus for high-quality sequencing data to support biomarker discovery, oncology research, and precision medicine.

13Whole Exome Sequencing (WES) Service
CategoryGenomics
Description

Protein-coding variant detection service providing high-depth coverage for precise identification of genetic mutations associated with disease, therapeutic response, and inherited conditions.

14Targeted NGS Panels Service
CategoryGenomics
Description

High-quality targeted next-generation sequencing panels optimized for accuracy, sensitivity, and comprehensive genomic coverage, enabling identification of clinically significant mutations across solid tumors and hematologic malignancies.

15Gene Expression Analysis Service
CategoryGenomics
Description

Multiplexed gene expression quantification using the NanoString nCounter platform, enabling analysis without amplification for biomarker discovery, pathway analysis, and immune profiling.

16qPCR / Sanger Sequencing Service
CategoryGenomics
Description

Targeted molecular analysis using Applied Biosystems ViiA 7 Real-Time PCR system for biomarker validation and gene expression profiling, and gold-standard Sanger sequencing using Applied Biosystems 3730xl Genetic Analyzer for validation of deep sequencing results.

17Flow Cytometry Service
CategoryBiomarker Development
Description

Cell analysis service for enumerating and phenotyping cells using a comprehensive library of CLIA-validated test panels, supporting full work-up on lymphoid and myeloid malignancies, with panels available for apoptosis and immuno-oncology exploration.

18Anatomical Pathology Services
CategoryHistopathology
Description

Digital pathology services including pathologist-directed image analysis, whole-slide brightfield and fluorescent scanning, multispectral imaging, and AI-powered image analysis using the proprietary Flotilla platform.

19Tissue Insight (TI) 22C3 NSCLC Digital Assay
CategoryDigital Assay
Description

Digital assay for quantifying PD-L1 in non-small cell lung cancer, validated and published in Scientific Reports as a technology to streamline the PD-L1 IHC quantification process.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-23
Description

Flagship Biosciences and Offspring Biosciences formed a strategic partnership to provide complete global assay development services from target identification to companion diagnostics. The partnership combines Offspring's innovative pre-clinical biomarker assay solutions with Flagship's clinical trial data-driven assay solutions, providing a full end-to-end solution with a North American and European footprint. Flagship CEO Trevor Johnson expressed confidence that the combined offerings would bring unique and valuable translational and clinical capabilities to development partners.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-02-07
Description

Flagship Biosciences partnered with Genomenon to advance precision medicine development. Genomenon's genomic landscapes (Master Genomic Database and AI-powered genomic interpretation) are integrated with Flagship's biomarker services and companion diagnostic development solutions, enhancing Flagship's ability to provide comprehensive genomic insights for rare disease and oncology research.

3Paige
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2022-02-17
Description

Paige, the global leader in AI-based diagnostic software in pathology, partnered with Flagship Biosciences to expand access to Flagship's AI-aided software for quantifying PD-L1 IHC stains across various tissue types. The partnership provides broader market access for Flagship's image analysis tools in immuno-oncology biomarker analysis.

flagshipbio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

NeoGenomics operates a Pharma Services division that provides biomarker, IHC, ISH, and molecular testing to support oncology clinical trials and companion diagnostics. It is one of the most direct competitors to Flagship in the biomarker CRO segment serving pharma and biotech sponsors.

TypeDirect peer
Description

CellCarta is a specialty biomarker and histopathology CRO focused on IHC, multiplex immunofluorescence, ISH, and flow cytometry for clinical trials and companion diagnostics. Its menu, multi-site lab footprint, and customer base overlap closely with Flagship's spatial biology and biomarker development services.

TypeDirect peer
Description

Akoya Biosciences develops spatial biology platforms (PhenoCycler, PhenoImager) and offers clinical research services including multiplex immunofluorescence and AI image analysis. It competes directly with Flagship in spatial profiling and digital pathology readouts for pharma and academic clients.

TypeDirect peer
Description

Paige develops AI-based diagnostic software for pathology and partners with pharma on AI-aided tissue image analysis, including PD-L1 IHC quantification alongside Flagship. Paige and Flagship are both partners and competitors in AI-enabled digital pathology services for clinical trials.

TypeDirect peer
Description

Personalis provides molecular diagnostics and biomarker services for oncology clinical trials, including whole-genome sequencing, ImmunoID Next, and ctDNA assays. It overlaps with Flagship's genomic and biomarker service offering for pharma drug development and companion diagnostic programs.

TypeEmerging player
Description

Bio-Techne offers spatial biology reagents (RNAscope, GeoMx partnership), proteomics, and ExoDx diagnostics, with services and tools that intersect Flagship's spatial biology and biomarker development workstreams. The overlap is partial — more on the reagent/kit side than pure services — but increasingly competitive on assay offerings.

TypeBroad incumbent
Description

Q² Solutions is IQVIA's central lab and biomarker services business, offering global clinical trial lab testing, genomics, flow cytometry, and anatomic pathology. It is a much larger incumbent competing with Flagship for biomarker and central lab work on enterprise pharma trials.

TypeBroad incumbent
Description

Fortrea is a large global CRO spun out of LabCorp with central labs, biomarker services, and clinical trial capabilities that overlap with Flagship's CRO offerings. It competes on enterprise pharma programs requiring end-to-end clinical lab support at much larger scale.

TypeBroad incumbent
Description

Charles River provides a broad portfolio of CRO and research services including discovery, safety assessment, and CDx/biomarker support through its research models and services segment. Its biomarker and CDx capabilities overlap with Flagship's clinical-stage assay development work, though at much broader scale.

TypeRegional player
Description

Eurofins Genomics is a global provider of genomic services (sequencing, genotyping, gene expression, bioinformatics) headquartered in Europe. It competes with Flagship's genomics offering and has a stronger European footprint, though it is less focused on spatial biology and tissue biomarker services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flagship Biosciences

Contract Research Organization (Biomarker and Spatial Biology Services)flagshipbio.com

Flagship Biosciences is a privately held CRO delivering AI-powered spatial biology, genomics, and histopathology services to pharmaceutical and biotech companies for clinical trials and companion diagnostic development. It operates CLIA-CAP-accredited laboratories in Colorado and North Carolina.

What Flagship Biosciences does

Flagship Biosciences is a privately held, US-based contract research organization that delivers spatial biology, genomics, and histopathology services to pharmaceutical and biotechnology companies conducting drug development and clinical trials. Founded in 2009 and headquartered in Broomfield, Colorado, with a second laboratory in Morrisville, North Carolina acquired from Interpace Pharma Solutions in 2022, the company operates CLIA-certified, CAP-accredited, and New York State-permitted facilities. Its service catalog spans immunohistochemistry, multiplex immunofluorescence, in situ hybridization, digital spatial profiling, RNA sequencing, whole-exome and whole-genome sequencing, targeted NGS panels, gene expression analysis, qPCR/Sanger sequencing, flow cytometry, and anatomical pathology, sold through Statement-of-Work engagements on a custom-quote basis.

The company's technical backbone is its proprietary Flotilla image analysis platform, which applies machine learning algorithms to clinical tissue samples, performing tissue segmentation, cell identification, and spectral unmixing while collecting thousands of features per cell to build cellular databases. Expert board-certified pathologists and computational scientists guide this AI through quality control and artifact detection, and the company has published validated digital assays such as Tissue Insight 22C3 NSCLC in Scientific Reports. Flagship also integrates third-party sequencing and spatial profiling instruments — Illumina NovaSeq, NanoString nCounter and GeoMx, Leica whole-slide scanners — into its workflow, and partners with Genomenon, Paige, and Offspring Biosciences to extend its genomic interpretation, immuno-oncology software distribution, and transatlantic assay development footprint.

Flagship generates revenue through professional-services CRO engagements with enterprise pharma and biotech clients, with pricing driven by project scope, assay complexity, sample volume, regulatory requirements, and turnaround time on multi-year Statement-of-Work contracts. The company sells directly through enterprise field sales supported by a conference-heavy marketing program (AACR, ASCO, World CDx, Spatial Biology summits), scientific content, and a quarterly newsletter, and is recognized via the Frost & Sullivan 2023 North American Customer Value Leadership Award in AI-enabled digital pathology.

Flagship Biosciences firmographics

Firmographics
Name
Flagship Biosciences
Legal name
Flagship Biosciences, Inc.
Website
https://flagshipbio.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Flagship Biosciences is a privately held CRO delivering AI-powered spatial biology, genomics, and histopathology services to pharmaceutical and biotech companies for clinical trials and companion diagnostic development. It operates CLIA-CAP-accredited laboratories in Colorado and North Carolina.
Ownership category
akta.pro rank

Flagship Biosciences industry classification

Industry
Product category
Contract Research Organization (Biomarker and Spatial Biology Services)
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAI
Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Spatial biology services
  • Biomarker analytics
  • Digital pathology
  • Companion diagnostics
  • Tissue imaging analysis

Where Flagship Biosciences is headquartered

Location

Headquarters

HQ city
Broomfield
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Flagship Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Biomarker and Spatial Biology Laboratory Services: Flagship Biosciences generates revenue through providing contract research organization (CRO) services including spatial biology, genomics, histopathology, and biomarker analytics to pharmaceutical and biotech companies for clinical trials. Revenue is project-based and service contract driven, typically scoped as Statement of Work agreements for specific assay development, testing, and analysis projects. The company operates CLIA-certified and CAP-accredited laboratories.
  2. Regulatory and Companion Diagnostics Development Services: Provides end-to-end regulatory strategy and companion diagnostic development services from early discovery through commercialization, including FDA interaction support, assay validation, and regulatory submission planning. Revenue generated through consulting and laboratory service engagements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing for pharma and biotech clients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Flagship Biosciences product offering

Product offering

Core offering

Flagship Biosciences provides AI-powered spatial biology, genomics, histopathology, and biomarker development services for pharmaceutical and biotech companies through CLIA-certified and CAP-accredited laboratories. Core offerings include immunohistochemistry (IHC), multiplex immunofluorescence (mIF), digital spatial profiling, in situ hybridization (RNAscope ISH), RNA sequencing, whole exome and whole genome sequencing, and regulatory support for companion diagnostic development, all powered by the proprietary Flotilla image analysis platform and supported by expert pathologist consultation.

Product overview

Flagship Biosciences is a technology-driven spatial biology and biomarker services company offering a comprehensive portfolio of laboratory and analytical services. The core offerings include Spatial Biology services (IHC, multiplex immunofluorescence, digital spatial profiling, and ISH), Genomics services (RNASeq, WES, WGS, targeted NGS panels, gene expression analysis, qPCR/Sanger sequencing), and Histopathology. These are supported by proprietary AI-powered image analysis technology (Flotilla platform), Computational Biology for data analysis, Biomarker Development, Regulatory Support for companion diagnostics, and Flow Cytometry. All services are delivered through a CLIA-certified, CAP-accredited laboratory with expert scientific consultation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Spatial Biology Services Comprehensive spatial biology services combining multiplexed in situ RNA detection (RNAscope), multiplex immunofluorescence (mIF), digital spatial profiling (NanoString GeoMx), and IHC with AI-powered image analysis. Sold to pharmaceutical and biotech companies for biomarker discovery, assay development, and clinical trial support.
  • Genomics Services CLIA-certified, CAP-accredited DNA sequencing and gene expression services including RNASeq, Whole Exome Sequencing, Whole Genome Sequencing, targeted NGS panels, gene expression analysis (NanoString nCounter), and qPCR/Sanger sequencing. Supports biomarker discovery, oncology research, and precision medicine programs.
  • Histopathology Services Histopathology services combining board-certified pathologist expertise with digital pathology and AI-powered analysis, including H&E, IHC, multiplex immunofluorescence, and special stains. Includes GLP and clinical trial support for pharma and biotech clients.
  • Image Analysis Services Cutting-edge imaging and proprietary image analysis software for tissue sample analysis at transcriptomics and proteomics levels, including multiplexed in situ RNA detection and multiplex immunohistochemical staining with AI and machine learning coupled with expert pathologist consultation.
  • ISH (In Situ Hybridization) Services RNA detection service using the RNAscope platform enabling highly sensitive, single-cell RNA detection within tissue samples for precise visualization of gene expression in native tissue context.
  • mIF (multiplex immunofluorescence) Services Advanced spatial biology service enabling simultaneous detection of multiple biomarkers on a single slide for immune profiling, biomarker co-localization, and pathway exploration. Combines custom panel development with proprietary image analysis and AI-driven quantification.
  • Digital Spatial Profiling (DSP) Services High-resolution biomarker expression analysis using the NanoString GeoMx platform, combining multiplexed RNA or protein quantification with precise spatial localization to uncover insights into tumor microenvironment, immune infiltration, and cellular heterogeneity.
  • Biomarker Development Services Assay development, validation, and operationalization services for rare diseases, oncology, and other therapeutic areas. Includes a robust library of fit-for-purpose and validated singleplex, duplex, and multiplex panels using IHC, ISH, and multiplex IF modalities.
  • Regulatory Support Services End-to-end regulatory support for biomarker development from early discovery through commercialization, including gap analysis, assay development strategies, FDA interface, LDT development, cutoff determination, and regulatory submission planning for companion diagnostics.
  • Computational Biology Services Data science services leveraging advanced analytical techniques for deriving insights from complex tissue image analysis and genomics data. Includes custom analysis using Bioconductor tools, StarAligner for RNA alignment, and DESeq2/GLMMer for differential expression models.
  • RNASeq Service RNA sequencing service for transcriptome analysis providing insights into gene expression, alternative splicing, and RNA editing across various sample types using the NovaSeq X Plus platform.
  • Whole Genome Sequencing (WGS) Service Comprehensive whole genome sequencing service using NovaSeq X Plus for high-quality sequencing data to support biomarker discovery, oncology research, and precision medicine.
  • Whole Exome Sequencing (WES) Service Protein-coding variant detection service providing high-depth coverage for precise identification of genetic mutations associated with disease, therapeutic response, and inherited conditions.
  • Targeted NGS Panels Service High-quality targeted next-generation sequencing panels optimized for accuracy, sensitivity, and comprehensive genomic coverage, enabling identification of clinically significant mutations across solid tumors and hematologic malignancies.
  • Gene Expression Analysis Service Multiplexed gene expression quantification using the NanoString nCounter platform, enabling analysis without amplification for biomarker discovery, pathway analysis, and immune profiling.
  • qPCR / Sanger Sequencing Service Targeted molecular analysis using Applied Biosystems ViiA 7 Real-Time PCR system for biomarker validation and gene expression profiling, and gold-standard Sanger sequencing using Applied Biosystems 3730xl Genetic Analyzer for validation of deep sequencing results.
  • Flow Cytometry Service Cell analysis service for enumerating and phenotyping cells using a comprehensive library of CLIA-validated test panels, supporting full work-up on lymphoid and myeloid malignancies, with panels available for apoptosis and immuno-oncology exploration.
  • Anatomical Pathology Services Digital pathology services including pathologist-directed image analysis, whole-slide brightfield and fluorescent scanning, multispectral imaging, and AI-powered image analysis using the proprietary Flotilla platform.
  • Tissue Insight (TI) 22C3 NSCLC Digital Assay Digital assay for quantifying PD-L1 in non-small cell lung cancer, validated and published in Scientific Reports as a technology to streamline the PD-L1 IHC quantification process.

Quantifiable outcome

  • Proprietary digital assay Tissue Insight (TI) 22C3 NSCLC published in Scientific Reports for streamlining PD-L1 IHC quantification in NSCLC

Companies that use Flagship Biosciences

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Flagship Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Flagship Biosciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Offspring BiosciencescoreStrategic or Co-development Partner · 23 January 2024Flagship Biosciences and Offspring Biosciences formed a strategic partnership to provide complete global assay development services from target identification to companion diagnostics. The partnership combines Offspring's innovative pre-clinical biomarker assay solutions with Flagship's clinical trial data-driven assay solutions, providing a full end-to-end solution with a North American and European footprint. Flagship CEO Trevor Johnson expressed confidence that the combined offerings would bring unique and valuable translational and clinical capabilities to development partners.
  • GenomenoncoreTechnology or Integration · 7 February 2023Flagship Biosciences partnered with Genomenon to advance precision medicine development. Genomenon's genomic landscapes (Master Genomic Database and AI-powered genomic interpretation) are integrated with Flagship's biomarker services and companion diagnostic development solutions, enhancing Flagship's ability to provide comprehensive genomic insights for rare disease and oncology research.
  • PaigecoreTechnology or Integration · 17 February 2022Paige, the global leader in AI-based diagnostic software in pathology, partnered with Flagship Biosciences to expand access to Flagship's AI-aided software for quantifying PD-L1 IHC stains across various tissue types. The partnership provides broader market access for Flagship's image analysis tools in immuno-oncology biomarker analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Flagship Biosciences competitors and assessment

Company assessment

Direct peers

  • NeoGenomics Laboratories: NeoGenomics operates a Pharma Services division that provides biomarker, IHC, ISH, and molecular testing to support oncology clinical trials and companion diagnostics. It is one of the most direct competitors to Flagship in the biomarker CRO segment serving pharma and biotech sponsors.
  • CellCarta (formerly HistoGeneX): CellCarta is a specialty biomarker and histopathology CRO focused on IHC, multiplex immunofluorescence, ISH, and flow cytometry for clinical trials and companion diagnostics. Its menu, multi-site lab footprint, and customer base overlap closely with Flagship's spatial biology and biomarker development services.
  • Akoya Biosciences: Akoya Biosciences develops spatial biology platforms (PhenoCycler, PhenoImager) and offers clinical research services including multiplex immunofluorescence and AI image analysis. It competes directly with Flagship in spatial profiling and digital pathology readouts for pharma and academic clients.
  • Paige.AI: Paige develops AI-based diagnostic software for pathology and partners with pharma on AI-aided tissue image analysis, including PD-L1 IHC quantification alongside Flagship. Paige and Flagship are both partners and competitors in AI-enabled digital pathology services for clinical trials.
  • Personalis: Personalis provides molecular diagnostics and biomarker services for oncology clinical trials, including whole-genome sequencing, ImmunoID Next, and ctDNA assays. It overlaps with Flagship's genomic and biomarker service offering for pharma drug development and companion diagnostic programs.

Emerging players

  • Bio-Techne: Bio-Techne offers spatial biology reagents (RNAscope, GeoMx partnership), proteomics, and ExoDx diagnostics, with services and tools that intersect Flagship's spatial biology and biomarker development workstreams. The overlap is partial — more on the reagent/kit side than pure services — but increasingly competitive on assay offerings.

Broad incumbents

  • Q² Solutions (IQVIA): Q² Solutions is IQVIA's central lab and biomarker services business, offering global clinical trial lab testing, genomics, flow cytometry, and anatomic pathology. It is a much larger incumbent competing with Flagship for biomarker and central lab work on enterprise pharma trials.
  • Fortrea (formerly LabCorp Drug Development): Fortrea is a large global CRO spun out of LabCorp with central labs, biomarker services, and clinical trial capabilities that overlap with Flagship's CRO offerings. It competes on enterprise pharma programs requiring end-to-end clinical lab support at much larger scale.
  • Charles River Laboratories: Charles River provides a broad portfolio of CRO and research services including discovery, safety assessment, and CDx/biomarker support through its research models and services segment. Its biomarker and CDx capabilities overlap with Flagship's clinical-stage assay development work, though at much broader scale.

Regional players

  • Eurofins Genomics: Eurofins Genomics is a global provider of genomic services (sequencing, genotyping, gene expression, bioinformatics) headquartered in Europe. It competes with Flagship's genomics offering and has a stronger European footprint, though it is less focused on spatial biology and tissue biomarker services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Flagship Biosciences social profiles

Digital presence

Flagship Biosciences compliance and trust

Trust signal

Compliance4 records

Flagship Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flagship Biosciences leadership team

Management profile

Number of profiles

Profiles12 records

Flagship Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flagship Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flagship Biosciences

What does Flagship Biosciences do?

Flagship Biosciences provides AI-powered spatial biology, genomics, histopathology, and biomarker development services for pharmaceutical and biotech companies through CLIA-certified and CAP-accredited laboratories. Core offerings include immunohistochemistry (IHC), multiplex immunofluorescence (mIF), digital spatial profiling, in situ hybridization (RNAscope ISH), RNA sequencing, whole exome and whole genome sequencing, and regulatory support for companion diagnostic development, all powered by the proprietary Flotilla image analysis platform and supported by expert pathologist consultation.

Is Flagship Biosciences a public or private company?

Flagship Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Flagship Biosciences founded?

Flagship Biosciences was founded in 2009. It employs 11 to 50 people.

Where is Flagship Biosciences based?

Flagship Biosciences is headquartered in Broomfield, United States, in the North America region.

How does Flagship Biosciences make money?

Two revenue lines are on record. Biomarker and Spatial Biology Laboratory Services are the primary driver. The others are regulatory and Companion Diagnostics Development Services.

Who are Flagship Biosciences's main competitors?

Direct peers on record are NeoGenomics Laboratories, CellCarta (formerly HistoGeneX), Akoya Biosciences, Paige.AI and Personalis. Bio-Techne is listed as an emerging player. Broad incumbents are Q² Solutions (IQVIA), Fortrea (formerly LabCorp Drug Development) and Charles River Laboratories. Eurofins Genomics is listed as a regional player.

Does Flagship Biosciences have an API?

No public API is recorded for Flagship Biosciences.

What industry is Flagship Biosciences in?

Flagship Biosciences's product category is Contract Research Organization (Biomarker and Spatial Biology Services). Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAI, Molecular Pathology & Tissue Biomarkers (IHC/ISH, digital pathology-linked markers). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingLanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology CapabilitiesLanterne Dx completed its merger with Flagship Biosciences, combining histopathology and biomarker services with computational pathology and digital tissue analysis. The combined organization will operate under the Lanterne Dx name, with Jon Bishop as CEO and Tom Turi retiring by year-end. The merger expands integrated biomarker and digital pathology capabilities for drug development.SecSEC FORM DFlagship Biosciences, Inc. filed a Form D with the SEC on April 16, 2024, announcing an exempt securities offering under Rule 506(b) that began on April 10, 2024. The company has raised $5 million of a total offering amount of approximately $6.37 million from three investors.PR NewswireFlagship Biosciences Applauded by Frost & Sullivan for Changing Biomarker Analysis to Find Biomarkers that Aid Drug Development and DiagnosticsFrost & Sullivan awarded Flagship Biosciences the 2023 North American Customer Value Leadership Award for its AI-enabled digital pathology and spatial biology solutions that enhance biomarker analysis for drug development and diagnostics. The company recently acquired Interpace Pharma Solutions, combining technologies to provide comprehensive molecular and tissue profile analysis across both liquid and tissue samples. Flagship reported a 90% customer retention rate, with Frost & Sullivan recognizing its consultative approach and customer-first strategy in the competitive digital pathology market.SecSEC FORM DFlagship Biosciences, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of securities under Rule 506(b). The filing indicates that the company raised a total of $15,285,339 USD from three investors in connection with a business combination transaction.FierceBiotechFlagship Biosciences snaps up Interpace's Pharma SolutionsFlagship Biosciences has acquired Interpace Biosciences' Pharma Solutions division to expand its biomarker analytics capabilities and add a laboratory in North Carolina. This acquisition supports Flagship's investment strategy from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies. The move integrates advanced molecular and genomic profiling services to enhance precision therapeutic development.BioSpaceInterpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.Interpace Biosciences closed a deal for Flagship Biosciences to acquire its Pharma Services business. The company expects operating cash flow to improve by nearly $5 million annually. Proceeds will fund working capital and investments in its molecular diagnostics business.GlobeNewswireInterpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.Interpace Biosciences closed a definitive asset purchase agreement with Flagship Biosciences, selling its Pharma Services business. The company expects operating cash flow to improve by nearly $5 million annually, and will use proceeds for working capital and investments in its molecular diagnostics business.The Globe and MailSpatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace BiosciencesFlagship Biosciences has acquired the Interpace Pharma Solutions business from Interpace Biosciences, expanding its portfolio of biomarker and analytics services. This strategic combination adds a state-of-the-art laboratory in Research Triangle Park, NC, to Flagship's capabilities in precision therapeutic development.FlagshipbioPaige and Flagship Biosciences Announce Partnership to Expand Access to Immuno-Oncology Biomarker Analysis ToolsPaige and Flagship Biosciences announced a partnership to integrate Flagship’s TissueInsight software into the Paige Platform, allowing pathologists to access AI-aided PD-L1 biomarker analysis tools directly. This integration aims to provide rapid, CLIA-reportable results and reduce variability in immunohistochemistry scoring for immuno-oncology therapies.InsideprecisionmedicineLeap, Flagship Collaborate to Use RNAscope for Image Analysis in Gastric Cancer TrialLeap Therapeutics and Flagship Biosciences have developed a CLIA-validated RNAscope assay with digital image analysis to prospectively enroll patients in a clinical trial for Leap's DKN-01 therapy. This collaboration aims to identify gastric/gastroesophageal junction adenocarcinoma patients with elevated DKK1 RNA expression, thereby accelerating patient screening and improving the precision of clinical endpoints.